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A B S T R A C T
Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce
the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in
locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials.
Based on the results of the BILCAP phase III trial, capecitabine was adapted as the standard of care by the ASCO
clinical practice guideline. Ongoing randomized controlled trials mainly compare capecitabine with gemcita-
bine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC
based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).
1. Introduction
Biliary tract cancer (BTC) is a heterogeneous group of malignancies
of the bile ducts and gallbladder, and is anatomically classified into four
distinct subtypes: intrahepatic, perihilar, distal cholangiocarcinoma,
and gallbladder cancer. Considering the low incidence of BTC, these
four BTC subtypes together with periampullary carcinomas are usually
combined in clinical trials, mainly to ensure adequate accrual of pa-
tients. However, these BTC subtypes are considered as different diseases
with different risk factors, diagnostic work-up, genomic mutation pro-
files, and surgical and systemic treatment options.(Valle et al., 2017)
Most important risk factors for cholangiocarcinoma in Western coun-
tries are primary sclerosing cholangitis, hepatic steatosis, and hepatitis
B and C.(Rizvi and Gores, 2013; Petrick et al., 2017) History of chole-
cystolithiasis is the strongest risk factor for gallbladder cancer.(Randi
et al., 2006) In the sixth edition of the American Joint Committee on
Cancer (AJCC) staging system, intrahepatic cholangiocarcinoma was
combined with hepatocellular carcinoma, and perihilar
cholangiocarcinoma with distal cholangiocarcinoma.(Cancer, 2002)
The seventh and eighth edition of AJCC have further subdivided BTC to
the four subtypes.(Valle et al., 2016; National Comprehensive Cancer
Network (NCCN), 2019)
Surgical resection is the only potentially curative treatment in lo-
calized BTC, but only a minority of patients (20%-30%) have resectable
disease at diagnosis.(Groot Koerkamp et al., 2015a; Zhang et al., 2017)
Despite extensive surgical resections, the five-year overall survival (OS)
remains poor (10%-40%) and a high proportion of patients (≥66%)
present with recurrence within five years after surgical resection.(Groot
Koerkamp et al., 2015a; Zhang et al., 2017; Ebata et al., 2018; Jarnagin
et al., 2003; Byrling et al., 2017) Local recurrence is the predominant
site of relapse in cholangiocarcinoma, whereas distant metastases are
more common in gallbladder cancer.(Groot Koerkamp et al., 2015a;
Jarnagin et al., 2003)
Various tumor characteristics are associated with increased rates of
disease-recurrence and poor survival following surgical resection.
(Hyder et al., 2014; Groot Koerkamp et al., 2015b; Wellner et al., 2017;
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Wang et al., 2011) Poor prognostic factors for intrahepatic cholangio-
carcinoma include advanced age, larger tumor size, multiple lesions,
positive regional lymph nodes, vascular invasion, and liver cirrhosis.
(Hyder et al., 2014) In perihilar cholangiocarcinoma, positive resection
margin, positive regional lymph nodes, and moderate or poor differ-
entiation grade are the most important prognostic factors for poor
disease-free survival (DFS).(Groot Koerkamp et al., 2015b) Positive
resection margin, perineural invasion, and undifferentiated adeno-
carcinoma were found to be prognostic in distal cholangiocarcinoma.
(Wellner et al., 2017) The prognostic factors for OS in gallbladder
cancer, based on data of 1,137 patients from the Surveillance, Epide-
miology and End Results (SEER)-Medicare, include advanced age, male
sex, African American or Asian/Pacific Islander race, larger tumor size,
positive regional lymph nodes, and whether patients received adjuvant
chemo(radio)therapy.(Wang et al., 2011) Based on these prognostic
factors various, prediction models have been developed and validated
to predict the survival of patients with BTC following surgical resection.
(Hyder et al., 2014; Groot Koerkamp et al., 2015b; Wang et al., 2011)
Various retrospective studies have investigated the efficacy of nu-
merous chemotherapeutic agents, in combination with or without
radiotherapy in the adjuvant setting, which previously demonstrated
activity in locally advanced and metastatic BTC. Recently, a systematic
review was published with 30 studies, including three prospective
studies, involving a total of 22,499 patients with BTC.(Ghidini et al.,
2017) A total of 3,967 patients received adjuvant chemotherapy,
mainly gemcitabine or fluoropyrimidine-containing schedules. In a
meta-analysis of patients treated with surgical resection, adjuvant
chemotherapy was associated with significantly longer OS (HR 0.59,
95% CI 0.49-0.71) compared to surgery only. In subgroup analyses, the
OS benefit in patients treated with adjuvant chemotherapy remained
statistically significant regardless of the status of resection margins (R0
or R1) and regional lymph nodes (N0 or N1).
To evaluate whether adjuvant therapy could increase loco-regional
control, prevent distant metastasis and improve survival of patients
with BTC, a number of phase II and III studies were initiated. This re-
view provides an update of adjuvant therapy in BTC based on the
available phase II and III trials (Table 1) and discusses the ongoing
randomized clinical trials (Table 2), divided into six sections based on
the backbone of the (neo-)adjuvant therapy.
2. Adjuvant gemcitabine-based chemotherapy
2.1. Gemcitabine
Gemcitabine monotherapy has been used for several years in locally
advanced and metastatic BTC until the publication of the ABC-02 phase
III trial in 2010. This trial has shown that gemcitabine plus cisplatin is
associated with longer progression-free survival (median: 8.0 versus 5.0
months; HR 0.63, 95% CI 0.51-0.77) and OS (median: 11.7 versus 8.7
months; HR 0.64, 95% CI 0.52-0.80) compared to gemcitabine mono-
therapy.(Valle et al., 2010) Gemcitabine monotherapy was recently also
evaluated in two phase II and one phase III trials in the adjuvant setting.
It was initially hypothesized that the gemcitabine schedule as used in
locally advanced and metastatic BTC may result in increased adverse
events following hepatectomy, because gemcitabine is mainly meta-
bolized in the liver.(Kainuma et al., 2015; Kobayashi et al., 2011) For
this purpose, one of the first randomized phase II studies in the adjuvant
setting evaluated the feasibility and efficacy of two gemcitabine sche-
dules in BTC patients after extensive surgical operations, such as major
hepatectomy or pancreatoduodenectomy.(Kobayashi et al., 2011) A
total of 27 patients with BTC were enrolled in this study and rando-
mized between three-weekly gemcitabine for nine cycles and four-
weekly gemcitabine for six cycles. The primary endpoint was the
treatment completion rate without any dose modification, which was
23% versus 14% (P = 0.81) in the three-weekly gemcitabine versus
four-weekly gemcitabine arm, respectively. Neutropenia was the mostTa
bl
e1
(co
nti
nu
ed
)
Stu
dy
Ph
as
e
No
.w
ith
BT
C
(al
lp
ati
en
ts)
Di
sea
se
Sit
e
T3
-4
tu
mo
rs,
N
(%
)
No
de
Po
sit
ive
,
N
(%
)
Ma
rg
in
Po
sit
ive
,
N
(%
)
Tr
ea
tm
en
t
Me
dia
n
fol
low
-up
(m
o.)
Pr
im
ary
en
dp
oin
t
Re
cu
rre
nc
e-f
ree
su
rv
iva
lg
Ov
era
ll
su
rv
iva
l
Ch
oe
ta
l.3
6
(N
CT
00
66
06
99
)
IId
12
(5
0)
CC
A,
GB
C
13
/2
1f
(6
1.9
%)
15
/2
1f
(7
1.4
%)
NR
Ge
mc
ita
bin
e+
do
ce
tax
el
→
flu
or
ou
rac
il
+
rad
iot
he
rap
y→
ge
mc
ita
bin
e+
do
ce
tax
el
24
.0
AE
s
DF
S1
6.3
mo
(m
ed
ian
)
27
.6
mo
(m
ed
ian
)
N,
nu
mb
er;
mo
,m
on
th
s;
BT
C,
bil
iar
yt
rac
tc
an
ce
r;
CC
A,
ch
ola
ng
ioc
arc
ino
ma
;iC
CA
,in
tra
he
pa
tic
ch
ola
ng
ioc
arc
ino
ma
;p
CC
A,
pe
rih
ila
rc
ho
lan
gio
ca
rci
no
ma
;d
CC
A,
dis
tal
ch
ola
ng
ioc
arc
ino
ma
;G
BC
,g
all
bla
dd
er
ca
nc
er;
PC
,
pe
ria
mp
ull
ary
ca
rci
no
ma
;R
FS
,r
ec
ur
ren
ce
-fr
ee
su
rv
iva
l;
DF
S,
dis
ea
se-
fre
es
ur
viv
al;
OS
,o
ve
ral
ls
ur
viv
al;
AE
s,
ad
ve
rse
ev
en
ts.
a
Th
is
tri
al
ha
sa
lso
inc
lud
ed
pa
tie
nt
sw
ith
R2
res
ec
tio
ns
or
dis
tan
tm
eta
sta
sis
.H
R
sh
ow
na
re
on
ly
for
pa
tie
nt
sw
ith
cu
rat
ive
res
ec
tio
ns
,d
efi
ne
di
nt
his
tri
al
as
R0
an
dc
om
ple
te
res
ec
tio
no
f(
lym
ph
no
de
)m
eta
sta
sis
.
b
Nu
mb
er
of
pa
tie
nt
sw
ith
po
sit
ive
lym
ph
no
de
sw
as
giv
en
for
all
pa
tie
nt
sw
ith
CC
A
or
GB
C
inc
lud
ing
th
os
ew
ith
dis
tan
tm
eta
sta
ses
.
c
Me
dia
nf
oll
ow
-up
for
th
el
ivi
ng
pa
tie
nt
s.
d
Sin
gle
arm
stu
dy
.
e
Th
efi
rst
9
pa
tie
nt
sh
av
er
ec
eiv
ed
ad
juv
an
tg
em
cit
ab
ine
an
d
aft
er
pr
oto
co
la
me
nd
me
nt
21
pa
tie
nt
sr
ec
eiv
ed
ge
mc
ita
bin
ep
lus
cis
pla
tin
.N
o
sta
tis
tic
al
diff
ere
nc
ew
as
ob
ser
ve
d
in
su
rv
iva
lo
fp
ati
en
ts
tre
ate
d
wi
th
ge
mc
ita
bin
eo
rg
em
cit
ab
ine
plu
sc
isp
lat
in.
f
Pe
rce
nt
ag
ef
or
bil
iar
yt
rac
tc
an
ce
rp
ati
en
ts
an
dp
ati
en
ts
wi
th
am
pu
lla
ry
ca
rci
no
ma
.
g
Al
ls
tu
die
sa
re
RF
Se
xc
ep
to
th
erw
ise
ind
ica
ted
.
A. Belkouz, et al. Critical Reviews in Oncology / Hematology 151 (2020) 102975
3
common grade 3 adverse events (64% versus 69% in the three-weekly
gemcitabine versus four-weekly gemcitabine arm, respectively). After a
median follow-up of 17.0 months, the 2-year recurrence-free survival
(RFS) was 53% versus 55% (P = 0.83) and the two-year OS was 71%
versus 75% (P = 0.59) in patients treated with four-weekly versus
three-weekly gemcitabine scheme. A single-arm phase II trial assessed
the feasibility and safety of gemcitabine monotherapy following com-
plete surgical resection in 72 patients with BTC.(Woo et al., 2017)
Patients were enrolled within eight weeks after surgical resection and
received gemcitabine every four weeks for a total of six cycles. A
minority of patients had pT3-4 tumors (40.3%), positive regional lymph
nodes (44.4%), and all patients had microscopic negative resection
margin. After a median follow-up of 38.1 months, the median RFS (the
primary endpoint of the study) was 17.6 months (95% CI 9.2-37.6
months) and the median OS was 61.2 months (95% CI 24.7 months-not
reached). Neutropenia was the most common grade 3-4 adverse event
(55.6%).
Recently, the phase III Bile Duct Cancer Adjuvant Trial (BCAT)
randomized 225 patients with perihilar or distal cholangiocarcinoma
between adjuvant gemcitabine and observation.(Ebata et al., 2018) In
the treatment arm, 117 patients received gemcitabine every four weeks
for a total of six cycles. The majority of patients had pT3-4 tumors
(55.1%), and only a minority of patients had positive regional lymph
nodes (34.7%), or microscopic positive resection margin (11.1%). The
primary endpoint of this study was OS. After a median follow-up of 79.4
months, the median RFS and OS were 36.0 versus 39.9 months (P =
0.69) and 62.3 versus 63.8 months (P = 0.96) in the gemcitabine
versus observation arm, respectively. Frequently observed grade 3 or 4
adverse events in the treatment arm included neutropenia (58.4%) and
leucocytopenia (29.2%). In the subgroup analyses, no survival differ-
ence was observed between both arms when patients were stratified
according to resection margin (R0 versus R1) or lymph node status (N0
versus N1). However, the number of patients in these subgroup analyses
were limited and therefore it remains uncertain whether patients with
positive regional lymph nodes or positive resection margin could
benefit from adjuvant chemotherapy.
2.2. Gemcitabine plus cisplatin
Two phase II trials have studied the efficacy and safety of adjuvant
gemcitabine plus cisplatin in BTC. The first study (NCT01073839)
evaluated the feasibility and efficacy of adjuvant gemcitabine plus
cisplatin in 30 patients with BTC.(Siebenhuner et al., 2018) A total of
nine patients received gemcitabine every four weeks for six cycles and
the remaining 21 patients received after a protocol amendment gem-
citabine plus cisplatin every 3 weeks for a total eight cycles. The ana-
lysis of the primary endpoint (the frequency of adverse events) found
the study treatment to be feasible with neutropenia (33% versus 57%),
leucocytopenia (0% versus 38%), thrombocytopenia (11% versus 19%)
and fatigue (33% versus 19%) as the most common grade 3 or 4 adverse
events in patients treated with gemcitabine versus gemcitabine plus
cisplatin. After a median follow-up of 31.0 months, median DFS and OS
in all patients were 14.9 and 40.6 months, respectively. In patients
treated with gemcitabine monotherapy versus gemcitabine plus cis-
platin, median DFS (14.4 versus 28.8 months, P = 0.22) and OS (46.9
versus 36.9 months, P = 0.67) were not statistically significantly dif-
ferent. Another single-arm phase II study (UMIN000001294) has as-
sessed the feasibility and efficacy of gemcitabine plus cisplatin in 29
patients with BTC (n = 27) or ampullary carcinoma (n = 2).(Kainuma
et al., 2015) Patients received gemcitabine and cisplatin every three
weeks for a total of eight cycles. A total of 72% of these patients have
completed the planned adjuvant treatment. The primary endpoint of
this study was the feasibility and adverse events of this treatment. The
study treatment was found feasible with neutropenia (27%), anemia
(17%) and leucocytopenia (14%) as the most common grade 3 or 4
adverse events. After a median follow-up of 38.1 months, median OS
was not reached and median RFS was 37.4 months. The four-year OS
rate was 60%.
Table 2
Ongoing randomized phase II and III trials of adjuvant therapy.
Study N Disease Site Study population Experimental arm Control arm Primary
endpoint
Status accrual
(Estimated completion
date)
Phase III trials
ACTICCA-01
(NCT02170090)
781 CCA, GBC T1-4, N0-1, and R0-1 Gemcitabine + cisplatin Capecitabine RFS Ongoing
(April 2021)
ASCOT
(UMIN00001168)
440 CCA, GBC,
AoV
T1-4, N0-1, and R0-1 S-1 Observation OS Accrual completed
GEMOXCC
(NCT02548195)
286 iCCA T1-4, N1, and R0-1 or
other risk factorsa
Gemcitabine + oxaliplatin Capecitabine RFS Unknown
NCT02798510 140 pCCA, dCCA
GBC
pT2-4, and N1 or R1 Gemcitabine + capecitabine →
capecitabine + radiotherapy
(50.4GY)
Gemcitabine + capecitabine OS Ongoing
(April 2019)
GAIN
(NCT03673072)
300 CCA, iGBC CCA: T1-4, N0-1, and
R0-1
iGBC: pT2-3, and N0-
1
Gemcitabine + cisplatin →
(re-)resection →
gemcitabine + cisplatin
(Re-)resection →±adjuvant
therapy (by investigator's
choice)
OS Ongoing
(November 2024)
NCT03579758 264 iGBC pT1b-3, and N0-1 Gemcitabine + cisplatin →
re-resection → capecitabine
Re-resection → capecitabine OS Ongoing
(April 2026)
Phase II trials
NCT03079427 100 pCCA, dCCA T1-4, N1, and R0-1 Gemcitabine + cisplatin Capecitabine DFS Ongoing
(April 2021)
NCT03609489 40 CCA, GBC T1-4, N0-1, and R0-1 Capecitabine + Apatinib Capecitabine RFS Ongoing
(June 2021)
NCT03768531 16 CCA, GBC T1-4, N0-1, and R0-1 Nivolumab Nivolumab and cabrilizumab AEs Ongoing
(January 2023)
CCA, cholangiocarcinoma; iCCA, intrahepatic cholangiocarcinoma; pCCA, perihilar cholangiocarcinoma; dCCA, distal cholangiocarcinoma; GBC, gallbladder cancer;
iGBC, incidential gallbladder cancer; PC, periampullary carcinoma; RFS, recurrence-free survival; DFS, disease-free survival; OS, overall survival; AEs, adverse
events.
a One or more of these risk factors: lymphatic vessel or blood vessel invasion, multiple tumors, tumor size larger than 5 cm, and/or preoperative CA 19-9 more than
200 U/mL.
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2.3. Gemcitabine plus oxaliplatin
The PRODIGE 12/ACCORD 18 phase III trial randomized 196 pa-
tients with BTC to receive gemcitabine plus oxaliplatin for 12 cycles or
surveillance.(Edeline et al., 2019) A minority of enrolled patients had
pT3-4 tumors (35.6%), positive regional lymph nodes (36.6%) or mi-
croscopic positive resection margin (12.9%). After a median follow-up
of 46.5 months, median RFS (the primary endpoint of the study) was
30.4 versus 18.5 months in the treatment versus observation arm (P =
0.47). Median OS was not significantly different between gemcitabine
plus oxaliplatin and the observation arm (75.8 versus 50.8 months, P =
0.74). The treatment completion rate was 74%. In the subgroup ana-
lyses, no statistical difference in RFS or OS was observed between both
arms when stratified by resection margin (R0 versus R1) or lymph node
status (N0 versus N1 versus Nx). In the subgroup of patients with
gallbladder cancer, patients treated with gemcitabine plus oxaliplatin
had shorter RFS (HR 2.56, 95% CI 1.04-6.32) and OS (HR 3.39, 95% CI
1.17-9.83) compared to those in the observation arm. The treatment
was found feasible with peripheral neuropathy (18.0%), and neu-
tropenia (14.0%) as the most common grade 3 adverse events in the
treatment arm in the first six months of the trial. Grade 4 adverse events
were observed in 11% of the patients in the treatment arm including
neutropenia (3%).
3. Adjuvant fluoropyrimidines-based chemotherapy
3.1. Fluorouracil plus mitomycin C
In one of the early clinical adjuvant phase III trials in BTC 508
patients with BTC (n = 279), ampullary carcinoma (n = 56), or pan-
creatic cancer (n = 173) were randomized between adjuvant fluor-
ouracil plus mitomycin C and observation following surgical resection.
(Takada et al., 2002) Of note, this clinical trial included patients who
had undergone curative resections, defined in this study as a micro-
scopically radical resection (R0) of the primary tumor with removal of
regional lymph node, as well as patients who had undergone surgical
resections in the presence of peritoneal (4.3%), liver (5.7%), and other
metastasis (0.9%). The majority of patients with cholangiocarcinoma
(86.4%) and gallbladder cancer (93.8%) had positive regional lymph
nodes. In the subgroup of patients in whom a microscopically radical
resection was achieved (n = 123), the five-year OS (primary endpoint
of the study) in patients with cholangiocarcinoma (n = 72) treated with
adjuvant fluorouracil plus mitomycin C was not significantly different
compared to those in the observation arm (41.0% versus 28.3%, P =
0.48). The five-year DFS rate was 32.4% and 15.8% in the treatment
versus observation arm (P = 0.29). In patients with completely re-
sected gallbladder cancer (n = 51), the five-year OS in patients treated
with adjuvant fluorouracil plus mitomycin C compared to observation
was not statistically significant (46.4% versus 30.9%, P = 0.15). The
difference in five-year DFS was not statistically significant between
both arms (35.5% versus 25.0%, P= 0.12). In the subgroup analysis of
all patients with gallbladder cancer, except those with liver and/or
peritoneal metastasis, adjuvant chemotherapy was correlated with
significantly longer RFS (HR 0.57, P = 0.05) and OS (HR 0.55, P =
0.03) in the multivariate analysis compared to observation. The com-
pletion rates of fluorouracil treatment were 79.3% and 94.2% in pa-
tients with cholangiocarcinoma and gallbladder cancer, respectively.
Patients treated with adjuvant fluorouracil plus mitomycin C had
higher rates of adverse events, including leucocytopenia (12.9%), an-
orexia (22.4%) and nausea/vomiting (12.9%, compared to observa-
tion).
3.2. S-1
The oral fluoropyrimidine agent S-1, which has shown efficacy in
clinical trials in locally advanced and metastatic BTC (Kim et al., 2011;
Kim et al., 2008; Yoo et al., 2018), was studied in two phase II studies in
the adjuvant setting.(Morizane et al., 2013; Morizane et al., 2018) A
single-arm phase II study (UMIN000004051) included 33 patients with
completely resected BTC.(Nakachi et al., 2018) The majority of patients
had pT3-4 tumors (60.6%) and positive regional lymph nodes (51.5%)
and a minority of patients had positive microscopic resection margins
(9.1%). Patients were planned to receive S-1 every six weeks for a total
of four cycles. The primary endpoint was the treatment completion rate,
which was completed by 81.8% of patients. After a median follow-up of
37.0 months, median RFS was 18.9 months (95% CI 2.5-35.3 months).
The median OS was not reached and the three-year OS was 54.5%. The
most common grade 3 or 4 adverse events were neutropenia (18.1%)
and increased serum bilirubin (9.1%). This phase II study showed that
adjuvant S-1 is feasible following complete surgical resection and re-
sulted in the initiation of a phase III trial (UMIN00001168) to evaluate
the efficacy of adjuvant S-1, which has recently been completed with
the enrollment of 440 patients with BTC.(Nakachi et al., 2018; Ikeda
et al., 2017) Patients were randomized between adjuvant S-1 and ob-
servation following surgical resection. Patients in the treatment arm
were planned to receive S-1 every six weeks for a total of four cycles.
This trial included patients with positive or negative regional lymph
nodes who received complete surgical resection. The primary endpoint
of this trial is OS and the secondary endpoints are RFS and adverse
events.
3.3. Capecitabine
In the phase III BILCAP trial, 447 patients with BTC were rando-
mized to receive adjuvant capecitabine or observation after a complete
surgical resection.(Primrose et al., 2019) In the treatment arm, patients
received capecitabine every three weeks for a total of eight cycles. A
total of 47.0% of patients had positive regional lymph nodes and 37.6%
of the patients had a positive resection margin (R1). After a median
follow-up of 60.0 months, the difference in median OS (primary end-
point) in the capecitabine versus observation arm was not statistically
significant in the intention-to-treat analysis (51.1 versus 36.4 months, P
= 0.10). The median RFS was 24.4 (95% CI 18.6-35.9) versus 17.5
(95% CI 12.0-23.8) months in the capecitabine versus observation arm,
respectively (P= 0.69). Adjustment for nodal status, disease grade and
sex in the sensitivity analysis resulted in statistically significant differ-
ence in OS between both arms (HR 0.71, 95% CI 0.55-0.92). The au-
thors report in the study protocol that a sensitivity analysis will be
performed, but they did not specify for which variables they will adjust
their analyses. In the per-protocol analysis patients treated with cape-
citabine had significantly longer OS compared to those in the ob-
servation arm (53 versus 36 months, P = 0.03). In the subgroup ana-
lyses of the BILCAP trial, no statistical difference in OS was found
between both arms when stratified by resection margin (R0 versus R1)
or lymph node status (N0 versus N1). In the per-protocol analysis, the
median RFS in the capecitabine arm (25.9 months, 95% CI 19.8-46.3)
was not significantly longer than in the observation arm (17.4 months,
95% CI 12.0-23.7). The adverse events of capecitabine were considered
being acceptable, with hand-foot syndrome (20%), diarrhea (8%) and
fatigue (8%) as the most common grade 3 or 4 adverse events.
4. Adjuvant gemcitabine- versus fluoropyrimidines-based
chemotherapy
4.1. Gemcitabine versus S-1
The KHBO 1208 phase II study has evaluated the efficacy of gem-
citabine versus S-1 in the adjuvant setting.(Kobayashi et al., 2018) This
study randomized 70 patients with BTC between gemcitabine every two
weeks for 12 cycles and S-1 every six weeks for four cycles. The ma-
jority of patients had pT3-4 tumors (52.9%), and a minority of patients
had positive regional lymph nodes (45.7%) or positive resection margin
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(17.1%). The primary endpoint of this study was RFS. The difference in
1-year RFS ((62.9% versus 51.4%, P = 0.33) and 2-year RFS (51.4%
versus 31.4%, P = 0.09) were not significantly different between
gemcitabine versus S-1. The 1-year OS was significantly shorter in the
gemcitabine arm than in the S-1 arm (80.0% versus 97.1%, P = 0.02),
but the 2-year OS was not significantly different between both groups
(80.0% versus 60.0%, P = 0.07). There was a trend towards improved
OS for S-1 (HR 0.48, 95% CI 0.25-0.93, P = 0.06). The treatment
completion rate was 54.3% versus 42.9% in the gemcitabine versus S-1
arm, respectively. Grade 3 adverse events were less frequently observed
in the gemcitabine arm than in the S-1 arm including neutropenia
(8.5%versus 22.8%), leucocytopenia (5.6% versus 8.5%) and biliary
tract infection (5.6%versus 17.1%). No grade 4 adverse events were
observed.
4.2. Gemcitabine versus fluorouracil plus folinic acid
The phase III European Study Group for Pancreatic Cancer-3
(ESPAC-3) included 428 patients with distal cholangiocarcinoma (n =
96) or periampullary carcinoma (n = 332).(Neoptolemos et al., 2012)
Patients were randomized between fluorouracil plus folinic acid, gem-
citabine or observation. The majority of enrolled patients had positive
regional lymph nodes (57.8%) and a minority of patients had a mi-
croscopic positive resection margin (15.7%). After a median follow-up
of 58.2 months, the difference in median OS (primary endpoint of the
study) between patients with distal cholangiocarcinoma treated with
gemcitabine, fluorouracil plus folinic acid or observation was not sig-
nificantly different (19.5 [95% CI 16.2-36.1], 18.3 [95% CI 12.9-28.7],
and 27.2 [95% CI 15.4-31.9] months, respectively). Most common
grade 3 or 4 adverse events of fluorouracil plus folinic acid versus
gemcitabine were neutropenia (24% versus 24%), leucocytopenia (8%
versus 10%), diarrhea (14% versus 4%), stomatitis (11% versus 0%)
and fatigue (10% versus 9%).
4.3. Gemcitabine plus oxaliplatin versus capecitabine
The phase III GEMOXCC trial (NCT02548195) was initiated in 2015
and has randomized 286 patients with intrahepatic cholangiocarcinoma
between gemcitabine plus oxaliplatin and capecitabine. Patients re-
ceived gemcitabine plus oxaliplatin every three weeks for six to eight
cycles or capecitabine every three weeks for eight cycles. Patients were
enrolled in this study if they had undergone complete surgical resection
(R0 or R1) with one or more of the following risk factors: positive re-
gional lymph node, lymphatic vessel or blood vessel invasion, multiple
tumors, tumor size larger than five cm, and/or preoperative CA 19-9
more than 200 U/mL. The primary endpoint is RFS and the secondary
outcomes are OS and adverse events. The planned number of patients
has been enrolled and definitive results are expected within a few years.
4.4. Gemcitabine plus cisplatin versus capecitabine
The ongoing phase III ACTICCA-01 trial was initiated in 2014 to
assess the efficacy and safety of adjuvant gemcitabine plus cisplatin
every three weeks for a total of eight cycles versus observation in pa-
tients with cholangiocarcinoma or muscle-invasive gallbladder cancer
following complete surgical resection.(Stein et al., 2015) After the
presentation of the BILCAP trial results in 2017 at the ASCO meeting,
the protocol has been amended to compare gemcitabine plus cisplatin
versus capecitabine every three weeksinstead of observation. Patients
stratification is based on lymph node status (N0 versus N1) and the
localization of the tumor. A total of 781 patients will be included from
various centers in Europe and Australia. The primary endpoint is RFS
and the secondary endpoints are OS, adverse events, and quality of life.
5. Adjuvant chemoradiotherapy
The feasibility and efficacy of adjuvant chemoradiotherapy was
recently evaluated by two prospective studies. The first phase II study
was initiated in 2003 and has enrolled patients with BTC (n = 12),
ampullary carcinomas (n = 9), and pancreatic cancer (n = 29).(Cho
et al., 2015) The majority of patients had pT3-4 tumors (61.9%) or
positive regional lymph nodes (71.4%). Patients were treated with 2
cycles of gemcitabine plus docetaxel every three weeks before and after
fluorouracil-based chemoradiotherapy (50.4-54.0 Gy). The addition of
a taxane to gemcitabine was based on the promising results from phase
II studies in locally advanced and metastatic BTC and pancreatic cancer.
(Kuhn et al., 2002; Lutz et al., 2005) The primary endpoint of the study
was the frequency of adverse events. The study treatment was found
feasible with neutropenia (23%), diarrhea (15%), and infection (15%)
as the most common grade 3 or 4 adverse events. After a mean follow-
up of 24 months, median DFS and OS in the 12 patients with BTC were
16.3 months (95% CI 5.8-57.1) and 27.6 months (95% CI 9.5-57.1),
respectively.
The Southwest Oncology Group (SWOG S0809) is a phase II study
that included 79 patients with perihilar or distal cholangiocarcinoma (n
= 54) or gallbladder cancer (n = 25) with positive lymph nodes, po-
sitive resection margin or pT2-4 after a complete resection.(Ben-Josef
et al., 2015) A minority of patients had a microscopic positive resection
margin (31.6%), and the proportion of patients with pT3-4 tumors or
positive regional lymph nodes was not reported. These patients were
treated with four cycles of gemcitabine plus capecitabine every three
weeks followed by capecitabine-based chemoradiotherapy (54.0-59.4
Gy). Approximately 86% of patients completed the planned treatment.
The two-year DFS and OS rates were 52% (95% CI 40%-62%) and 65%
(95% CI 53%-74%), respectively. The DFS and OS were not sig-
nificantly different between patients with R0 and R1 resection margins.
About 52% and 11% of patients had grade 3 or 4 adverse events, re-
spectively. The most common grade 3 or 4 adverse events were neu-
tropenia (44%) and hand-foot syndrome (11%).
Based on these promising results from the SWOG S0809 study, a
phase III trial (NCT02798510) was initiated in April 2016.(Clinical
Trials. gov. National Library of Medicine (US), 2019) A total of 140
patients with perihilar or distal cholangiocarcinoma, or gallbladder
cancer will be enrolled in this trial. Patients are eligible if they have a
negative macroscopic resection margin with positive or negative re-
gional lymph nodes. Patients are randomized between adjuvant gem-
citabine plus capecitabine every three weeks followed by capecitabine-
based chemoradiotherapy (50.4 Gy) or adjuvant gemcitabine plus ca-
pecitabine for a total of six cycles. The primary endpoint of the study is
OS. The accrual status is unknown at this moment (expected completion
date of accrual was April 2019).
6. Adjuvant targeted and immunotherapy in combination with
chemotherapy
Vascular endothelial growth factor receptor (VEGFR) is present in
the majority of patients with BTC (40% to 75%) and overexpression of
VEGF has been associated with development of metastasis in patients
with intrahepatic cholangiocarcinoma.(Valle et al., 2017; Yoshikawa
et al., 2008) In locally advanced and metastatic BTC, a phase II study
showed that addition of cediranib, a VEGFR1, 2 and 3 tyrosine kinase
inhibitor, to gemcitabine plus cisplatin had an improved response rate
compared to only gemcitabine plus cisplatin (44% versus 19%, P =
0.004), but the median progression-free survival (HR 0.93, 95% CI
0.65-1.35) and OS (HR 0.86, 95% CI 0.58-1.27) were not significantly
different.(Valle et al., 2015) In the adjuvant setting, a randomized
phase II study (NCT03609489) was recently initiated to evaluate the
efficacy and safety of apatinib, a VEGFR-2 tyrosine kinase inhibitor, in
combination with capecitabine compared to capecitabine monotherapy.
A total of 40 patients with BTC are randomized between capecitabine
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with or without apatinib every three weeks for a total of eight cycles.
The primary endpoint is RFS and the estimated accrual completion date
is June 2021.
Immune checkpoint inhibitors with monoclonal antibody targeting
the programmed cell death 1 (PD-1) have shown promising results in
locally advanced and metastatic BTC.(Bang et al., 2015) Recently, 24
patients were treated in the KEYNOTE-28 study with the anti-PD-1
antibody pembrolizumab.(Bang et al., 2015) Four patients had a partial
response and four patients achieved stable disease. Five of these pa-
tients had a long-term response and remained on treatment for more
than 40 weeks. Recently, a phase II study (NCT03768531) was initiated
to evaluate the safety and efficacy of the anti-PD-1 antibody nivolumab
plus cabiralizumab, a monoclonal antibody targeting macrophages and
monocytes, as neoadjuvant and adjuvant therapy in resectable BTC. A
total of 16 patients will be randomized between nivolumab and nivo-
lumab plus cabiralizumab every two weeks before and after surgical
resection. The primary endpoint is the occurrence of adverse events and
secondary endpoints are DFS and OS. The accrual of patients is ex-
pected to be completed in January 2023.
7. Combined neoadjuvant and adjuvant chemotherapy
Some retrospective studies have suggested a possible increase in
complete resection rates after neoadjuvant chemotherapy in BTC.
(Benjamin et al., 2017; Kobayashi et al., 2016) Recently, two rando-
mized phase III trials were initiated to assess the safety and efficacy of
perioperative chemotherapy. The phase III GAIN trial (NCT03673072)
was initiated in Germany and plans to randomize 300 patients between
neoadjuvant gemcitabine plus cisplatin followed by resection of cho-
langiocarcinoma or re-resection of incidental gallbladder cancer and
adjuvant gemcitabine plus cisplatin, or (re-)resection with or without
adjuvant chemotherapy based on the investigator's choice. Patients will
receive gemcitabine plus cisplatin every three weeks. In case of in-
cidental gallbladder cancer, patients are only eligible if they have a
pT2-3 tumor. The primary endpoint is OS and the estimated date of
completion of accrual is November 2024.
A phase III (NCT03579758) was recently initiated and plans to
enroll 264 patients with incidental gallbladder cancer discovered
during a simple cholecystectomy done for initial suspicion of benign
disease. Patients are eligible if they have a pT1b-T3 tumor. Patients are
randomized between four cycles of neoadjuvant gemcitabine plus cis-
platin every three weeks followed by re-resection and eight cycles of
adjuvant capecitabine every three weeks, and re-resection followed by
eight cycles of adjuvant capecitabine every three weeks. The primary
endpoint is OS and the accrual is expected to be completed in July
2025.
8. Recommendations from international guidelines
The American Society of Clinical Oncology (ASCO, 2019) clinical
practice guideline recommends adjuvant capecitabine for a duration of
six months based on the results of the BILCAP trial.(Shroff et al., 2019)
This guideline suggests also that patients with perihilar, distal cho-
langiocarcinoma, or gallbladder cancer and positive surgical resection
margin may be candidates for adjuvant chemoradiotherapy.
In the European Association for Medical Oncology (ESMO, 2016)
guideline and the National Comprehensive Cancer Network (NCCN)
guideline (version 3.0, 2019) for BTC, the results of the BILCAP trial
were not yet adopted. The ESMO guideline does not recommend ad-
juvant therapy due to the absence of positive results from randomized
phase III trials.(Valle et al., 2016) The ESMO guideline indicates that
patients should be encouraged to participate in clinical trials and that
outside the scope of clinical trials a multidisciplinary team may choose
to offer adjuvant treatment (chemotherapy alone, chemoradiotherapy,
or radiotherapy alone) to patients based on the best available evidence
and only after considering the adverse events against the expected
benefit from this treatment.(Valle et al., 2016) The NCCN guideline
(version 3.0, august 2019) suggest various adjuvant treatment options
mainly based on data from phase II trials.(National Comprehensive
Cancer Network (NCCN), 2019) The NCCN guideline does not define a
standard regimen or the definitive benefit from each suggested treat-
ment because of limited available data. Possible adjuvant treatment
options in patients with a negative microscopic resection margin and
tumor-positive regional lymph nodes include: observation, gemcita-
bine-based chemotherapy, or fluoropyrimidine-based chemo(radio)
therapy. In case of positive microscopic resection margin or tumor in-
volvement of regional lymph nodes, adjuvant therapy options include
among others: gemcitabine-based chemotherapy or fluoropyrimidine
chemo(radio)therapy. Participation in clinical trials is recommend for
all patients regardless of the status of resection margin and regional
lymph nodes.
9. Discussion
Current results of prospective trials provide conflicting evidence
regarding the role of adjuvant chemotherapy. The BCAT trial has shown
that adjuvant gemcitabine is not associated with improved RFS or OS.
(Ebata et al., 2018) Moreover, the combination of adjuvant gemcitabine
plus oxaliplatin did not appear to be effective in BTC as shown by the
PRODIGE 12 trial.(Edeline et al., 2019) Adjuvant fluorouracil plus fo-
linic acid was not superior to adjuvant gemcitabine or observation as
shown by the ESPAC-3 trial.(Neoptolemos et al., 2012) However, an
improved OS in gallbladder cancer patients has been observed upon
treatment with fluorouracil plus mitomycin C compared to observation.
(Takada et al., 2002) The BILCAP trial is the only phase III study that
has so far shown a benefit in OS in all BTC patients for treatment with
adjuvant capecitabine compared to observation.(Primrose et al., 2019)
Although the benefit in OS was not statistically significant in the in-
tention-to-treat analysis, the absolute survival benefit of 14.7 months
for the capecitabine group is considered clinically relevant.(Primrose
et al., 2019) The role of adjuvant chemoradiotherapy was evaluated in
two phase II trials.(Cho et al., 2015; Ben-Josef et al., 2015) These two
trials showed promising results with median OS of 26.0-27.6 months.
(Cho et al., 2015; Ben-Josef et al., 2015) The results of one of these two
trials (SWOG S0809) has led to the initiation of an ongoing phase III
trial (NCT02798510).(Ben-Josef et al., 2015)
The differences in the outcomes of available adjuvant trials may be
explained by inadequate power to identify significant difference in
RFS/DFS or OS.(Shroff et al., 2019) The BCAT trial was terminated
before the planned number of 300 patients were enrolled due to low
accrual, and the number of events was lower than expected. This could
have resulted in underpowered analyses, but this was unlikely ac-
cording to the authors of this trial because the survival curves almost
overlap.(Ebata et al., 2018; Shroff et al., 2019) In the PRODIGE 12 trial,
the precision of the estimated hazard ratio for the primary outcome
(RFS) was low.(Shroff et al., 2019) The expected median RFS (18.5 and
30.4 months) were almost comparable with the observed median RFS
(18 and 30 months), but the observed hazard ratio (0.88) was higher
than estimated (0.60).(Edeline et al., 2019) The BILCAP trial had an
inclusion period of ten years and a minimum follow-up of two years
leading to observation of more events for primary outcome (OS, 54.8%
were deceased) compare to BCAT (52.8% were deceased) and the
PRODIGE 12 trial (41.8% were deceased). In the BILCAP trial, the
treatment effect on OS was initially underestimated (improvement two-
year OS from 20% to 32%, HR 0.71). However, during the study the
observed number of events was lower than expected(Primrose et al.,
2019) which has led to a protocol amendment. In this amendment, the
number of events needed for the final analyses were reduced from 270
to 234 events and the expected two-years OS was increase from 60% to
71% (HR 0.69). The details about sensitivity and per-protocol analyses
were not specified in in the BILCAP study protocol.(Primrose et al.,
2019) These outcomes are unlikely to be reported if the primary
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outcome was statistical significant or if the sensitivity and per-protocol
analyses were not statistical significant.(NVMO-commissie, 2019) De-
spite that the toxicities of adjuvant capecitabine were considered as
acceptable, 32% of patients discontinued treatment due to adverse
events.(Primrose et al., 2019)
The difference in inclusion criteria between these trials could be
another explanation for the difference in outcome. Most studies have
enrolled patients with different BTC subtypes and proportions of risk
factors. The PRODIGE 12 trial has enrolled more patients with in-
trahepatic cholangiocarcinoma than the BILCAP trial (44% versus
19%).(Edeline et al., 2019) Moreover, different proportions of high-risk
features, such as pT3-4 tumor stage, tumor-positive regional lymph
nodes and/or positive resection margins, were included in these trials.
The BILCAP trial enrolled a large proportion of patients with high risk
features than The BCAT and PRODIGE 12 trials (N1, 47.0% versus
34.7% and 36.6%; R1-resection, 37.6% versus 11.1% and 12.9%, re-
spectively) which could explain the worse median RFS and OS in the
BILCAP study compared to the BCAT and PRODIGE 12 trials (Table 1).
It remains unclear whether all subtypes of BTC and patients with low
risk features will benefit from adjuvant capecitabine based on the
subgroup analysis of the BILCAP trial.
10. Conclusion
In conclusion, the results of the BILCAP trial has introduced cape-
citabine as the new standard for adjuvant treatment of BTC by the
ASCO clinical practice guideline. Given that this trial did not met its
primary endpoint, guidelines may recommend capecitabine as an ad-
juvant treatment to discuss with patients or recommend participation in
ongoing clinical trials. The NCCN and ESMO guidelines are expected to
adapt this adjuvant treatment recommendation in the updated versions
of their guidelines. The results of the ongoing ACTICCA-01 trial will
define whether gemcitabine plus cisplatin is superior to capecitabine.
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